TrialPanorama/Dataset huggingface dataset:
Please assess the completion status of the following clinical trial:

Trial Title: Combination Chemotherapy in Treating Patients With Extensive Stage Small Cell Lung Cancer

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: None
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: None
- Phase: PHASE3
- Number of Arms: None

Eligibility Criteria:
DISEASE CHARACTERISTICS: Histologically proven extensive stage small cell lung cancer Extends beyond hemithorax and supraclavicular lymph nodes Pleural effusions allowed Bidimensionally measurable disease Bone marrow metastases allowed No symptomatic CNS metastases or carcinomatous meningitis~PATIENT CHARACTERISTICS: Age: 18 to 75 Performance status: 0-2 Life expectancy: Not specified Hematopoietic: Neutrophil count at least 2,000/mm3 Platelet count at least 100,000/mm3 Hepatic: Bilirubin no greater than 1.5 times normal Renal: Creatinine less than 1.24 mg/dL OR Creatinine clearance greater than 60 mL/min Cardiovascular: No cardiac insufficiency No uncontrolled cardiac disease LVEF greater than 50% OR ECHO greater than 30% Other: Not pregnant Fertile patients must use effective contraception No psychoses No active infection No loss of weight greater than 10% during the last 3 months No other malignancy except nonmelanomatous skin cancer or stage I cervical cancer~PRIOR CONCURRENT THERAPY: Biologic therapy: No prior or concurrent immunotherapy Chemotherapy: No prior or other concurrent chemotherapy Endocrine therapy: Not specified Radiotherapy: No prior or concurrent radiotherapy Surgery: No prior or concurrent surgery

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 75 Years
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Levetiracetam: The Anti-Convulsant of Choice for Elderly Patients With Dementia

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Able to give written informed consent~* Meet validated clinical criteria for Alzheimer's disease, mixed dementia or MCI~* Age range greater than or equal to 60 years~* Stable general medical condition as assessed by the investigator~* Seizures which are partial in onset (with or without secondary generalization)~* Subjects with 4 or fewer seizures per month~* MMSE score of less than 28 at baseline~* Patients who are currently being treated with anticonvulsants or those with new onset seizures.~Exclusion Criteria:~* Patients with other clinically significant organic or neurological diseases. Patients considered medically unstable~* Patients in end stage renal disease requiring hemodialysis~* Patients with a known hypersensitivity to Levetiracetam~* Patients with primary generalized epilepsy~* Patients with brain tumors or other significant CNS abnormalities that are the primary cause of the seizures~* Patients with a history of status epilepticus~* Patients with severe psychiatric diagnoses or severe behavioral problems~* Dementia patients lacking a caregiver.

- Gender: ALL
- Minimum Age: 60 Years
- Maximum Age: 90 Years
- Healthy Volunteers: f

Study Arms:
- Levetiracetam (Type: EXPERIMENTAL): Levetiracetam was titrated over 4 weeks, with initial dosing of 250 mg bis in die (BID). Dosing was flexible and was based on the prescribing physician's discretion.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: BI 695501 Versus Humira in Patients With Active Crohn's Disease: a Trial Comparing Efficacy, Endoscopic Improvement, Safety, and Immunogenicity

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion criteria:~* Males and females aged \>=18 and =\<80 years at Screening who have a diagnosis of moderate to severely active Crohn's Disease (CD), confirmed by endoscopy or radiologic evaluation, for more than 4 months with evidence of mucosal ulceration. Patients must have all of the following:~  * Crohn's Disease Activity Index (CDAI) score of \>=220 and =\<450~ * A diagnosis of Crohn's Disease (CD) confirmed by ileocolonoscopy during Screening~ * Presence of mucosal ulcers in at least one segment of the ileum or colon and a SES-CD score ≥7 (for patients with isolated ileal disease SES-CD score ≥4), as assessed by ileocolonoscopy and confirmed by central independent reviewer(s) before randomization~* Anti-tumor necrosis factor (TNF) patients or patients previously treated with infliximab who had initially responded and who meet one of the following criteria:~  * Responded and developed secondary resistance due confirmed anti-infliximab anti-drug antibody formation, which caused infliximab depletion~ * Responded and became intolerant~* Further inclusion criteria apply~Exclusion criteria:~* Patients with ulcerative colitis or indeterminate colitis~* Patients with symptomatic known obstructive strictures~* Surgical bowel resection performed within 6 months prior to Screening or planned resection at any time while enrolled in the trial~* Patients with an ostomy or ileoanal pouch~* Patients with short bowel syndrome~* Patients who have previously used infliximab and have never clinically responded~* Patients who have previously received treatment with adalimumab, or who have participated in an adalimumab or adalimumab biosimilar clinical trial~* Further exclusion criteria apply

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 80 Years
- Healthy Volunteers: f

Study Arms:
- BI 695501 (Type: EXPERIMENTAL): None
- HUMIRA + BI 695501 (Type: ACTIVE_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Study to Evaluate Safety and Efficacy of Inhaled Bimosiamose for the Treatment of Patients With Moderate to Severe Chronic Obstructive Pulmonary Disease (COPD)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: CROSSOVER
- Observational Model: None
- Primary Purpose: None
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Male and postmenopausal or sterile female patients with a history of moderate to severe COPD defined as Global Initiative for Chronic Obstructive Lung Disease (GOLD) II-III for at least 1 year~* At least 40 years of age~* Current smoker or ex-smoker with at least 10 pack-year smoking history (Ten pack-years is defined as 20 cigarettes a day for 10 years, or 10 cigarettes a day for 20 years etc.)~* Postbronchodilator FEV1 between 30% and 80% predicted and FEV1/FVC ratio \< 70%. Postbronchodilator refers to 30 min after inhalation of 400 µg Salbutamol. This criterion for FEV1 will have to be demonstrated after a washout period of at least 48 h during which no long acting anticholinergic medication (LAMA) or long acting β2-agonists (LABA) has been inhaled or a washout period of 6 h during which no short acting β2-agonists (SABA) or anticholinergic medication (SAMA) has been inhaled. For patients having been pretreated with an inhaled corticosteroid (ICS) and/or theophylline, this criterion needs to be demonstrated after a washout of at least 4 weeks.~* Able to produce sputum upon induction in a sufficient quality. This criterion will be checked by the responsible sputum lab prior to randomization of the patient.~* Time and ability to complete the study~* Able to communicate well with the investigator, to understand and comply with the requirements of the study. Understand and sign the written informed consent.~Exclusion Criteria:~* Patients with a history of chronic respiratory disorders other than COPD e.g. asthma, α1-Antitrypsin deficiency, mucoviscidosis, lung fibrosis~* Patients who experienced an exacerbation in the 4 weeks before the screening visit or between screening and randomization~* Patients who experienced an acute upper respiratory tract infection or broncho-pulmonary infection requiring antibiotic treatment during the 4 weeks before the screening visit or between screening and randomization~* Treatment with inhaled (ICS), topical or any systemic corticosteroids or theophylline within at least 4 weeks before the screening visit and throughout entire course of the study. Patients with ICS and/or theophylline treatment will undergo a washout of at least 4 weeks after signature of the informed consent and prior to the screening visit, where eligibility to enter the study will be assessed

- Gender: ALL
- Minimum Age: 40 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Bimosiamose (Type: ACTIVE_COMPARATOR): None
- Placebo (Type: PLACEBO_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Spironolactone for Reducing Proteinuria in Diabetic Nephropathy

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: CROSSOVER
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~The study is completed. Inclusion criteria was diabetic nephropathy~Exclusion Criteria:~Scr \>2 mg/dl and serum K \> 5meq/L

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 90 Years
- Healthy Volunteers: f

Study Arms:
- 1 (Type: OTHER): None
- 2 (Type: OTHER): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Umbilical Cord Blood Transplant for Congenital Pediatric Disorders

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 1.0

Eligibility Criteria:
INCLUSION CRITERIA:~* Patients less than 18 years of age.~* Patients with a congenital or acquired immunologic, hematological, or metabolic pediatric disease (including SCID) in which stem cell transplantation has been beneficial.~* Related or Unrelated Umbilical Cord Blood Unit with 0-1 antigen mismatch, 5-6 HLA- A and B (at low to intermediate resolution) and DRB1 (at high resolution).~* Total cryopreserved HSC graft cell dose must be 5 x 10\^7 or greater nucleated cells per kilogram recipient body weight.~* Lansky/Karnofsky scores 60 or greater.~* Patient has DLCO \> 50% predicted or FEV1 \> 50%, if applicable.~* Written informed consent and/or signed assent line from patient, parent or guardian.~EXCLUSION CRITERIA:~* Patients with uncontrolled infections as assessed by the principal investigator only. For bacterial infections, patients must be receiving definitive therapy and have no signs of progressing infection for 72 hours prior to starting conditioning. For fungal infections patients must be receiving definitive systemic antifungal therapy and have no signs of progressing infection for 1 week prior to enrollment. Progressing infection is defined as hemodynamic instability attributable to sepsis or new symptoms, worsening physical signs or radiographic findings attributable to infection. Persisting fever without other signs or symptoms will not be interpreted as progressing infection.~* Severe renal disease (creatinine \> 3X normal for age).~* Severe hepatic disease (direct bilirubin \> 3 mg/dL or SGOT \> 500).~* Patients with symptomatic cardiac failure unrelieved by medical therapy or evidence of significant cardiac dysfunction by echocardiogram (shortening fraction \< 20%).~* HIV positive.

- Gender: ALL
- Minimum Age: None
- Maximum Age: 17 Years
- Healthy Volunteers: f

Study Arms:
- Umbilical Cord Blood Transplant Treatment Plan (Type: EXPERIMENTAL): Busulfan, Cytoxan, Fludarabine, Cord Blood Stem Cell Infusion

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Cluster RCT of Co-administration Azithromycin, Albendazole & Ivermectin

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1. Residing in the community for at least three months;~2. Eligible to receive all three agents according to standard MDA criteria~Exclusion Criteria:~1. Not eligible to receive one or more drugs according to standard MDA criteria;~2. Less than 5 years of age (not eligible for ivermectin)\*\*~3. Pregnant women (azithromycin only, not eligible for albendazole and ivermectin)~4. Lactating women (Only administered azithromycin and albendazole, not eligible for ivermectin)\*\*~5. History of allergies to the drugs being studied (azithromycin, ivermectin, albendazole)~6. Residents who cannot swallow tablets~   * Note that patients that are not eligible for IVM, will receive azithromycin and albendazole. Patients that receive azithromycin and albendazole will be followed up through the same procedure as the triple drug therapy to try to track any AEs attributed to the two drug combination.

- Gender: ALL
- Minimum Age: None
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Separate Administration (Type: ACTIVE_COMPARATOR): Standard administration of Albendazole/Ivermectin separated from administration of azithromycin
- Co-administration (Type: EXPERIMENTAL): Combined administration of Albendazole/Ivermectin/Azithromycin at a single time point

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: 13-valent Pneumococcal Conjugate Vaccine Study in Adults and Children in India

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~Indian adults subjects between 50 and 65 years of age and indian children between 6 and 17years of age, determined by clinical judgment to be eligible for 13vPnC vaccination.~Exclusion Criteria:~Any contraindication to 13vPnC vaccination, vaccination with any pneumococcal vaccine within the last year

- Gender: ALL
- Minimum Age: 6 Years
- Maximum Age: 65 Years
- Healthy Volunteers: t

Study Arms:
- 1 (Type: EXPERIMENTAL): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: NSAID Treatment in Knee Osteoarthritis

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 6.0

Eligibility Criteria:
Inclusion Criteria:~Patients eligible for the study were:~* older than 50 years and~* had primary knee OA diagnosed according to the clinical and radiological criteria of the American Rheumatism Association.~Further inclusion criteria were:~* clinical signs of joint inflammation (warmth, swelling or effusion) and~* a disease severity grade 2 or 3 according to the Kellgren-Lawrence classification~Exclusion Criteria:~* allergy to NSAIDs,~* progressive serious medical conditions (such as cancer, AIDS or end-stage renal disease),~* history of gastrointestinal ulcer or bleeding,~* a hemoglobin concentration lower than 11.5 g/dL,~* renal diseases (serum creatinine concentration more than 1.2 times the upper limit of the normal range according to the central laboratory definition reference values), or~* liver dysfunction (serum alanine or aspartate transaminase concentrations more than 1.5 times the upper limit of normal range according to the central laboratory definition reference values).

- Gender: ALL
- Minimum Age: 50 Years
- Maximum Age: 85 Years
- Healthy Volunteers: f

Study Arms:
- diclofenac 75 mg/day (Type: ACTIVE_COMPARATOR): diclofenac 75 mg once day slow release
- diclofenac 150 mg/day (Type: ACTIVE_COMPARATOR): diclofenac 75 mg bid
- ibuprofen 1200 mg/day (Type: ACTIVE_COMPARATOR): ibuprofen 600 mg bid
- ibuprofen 1800 mg/day (Type: ACTIVE_COMPARATOR): ibuprofen 600 mg tid
- celecoxib 200 mg/day (Type: ACTIVE_COMPARATOR): celecoxib 200 mg once day
- celecoxib 400 mg/day (Type: ACTIVE_COMPARATOR): celecoxib 200 mg bid

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Retention and Duration of Activity of SPL7013 (VivaGel®) After Vaginal Dosing.

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1/PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Healthy women aged 18-45 with regular menstrual cycles, free from sexually transmitted infections and using adequate contraception~Exclusion Criteria:~* Any condition, including genital conditions, sexually transmitted infection, menopause, and/or allergies that would make the study participant unsuitable for the study.~* Pregnancy or breast-feeding

- Gender: FEMALE
- Minimum Age: 18 Years
- Maximum Age: 45 Years
- Healthy Volunteers: t

Study Arms:
- Open Label, only arm (Type: EXPERIMENTAL): 3%w/w SPL7013 vaginal gel (VivaGel)

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Safety and Efficacy Study of A0001 in Subjects With Friedreich's Ataxia

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE2
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* Individuals with genetically confirmed Friedreich's Ataxia (GAA or point mutation)~* Impaired Glucose Tolerance, measured by Oral GTT~Exclusion Criteria:~* Overt Diabetes Mellitus~* Presence of clinically significant cardiovascular disease

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 60 Years
- Healthy Volunteers: f

Study Arms:
- Low Dose (Type: EXPERIMENTAL): A0001 (0.5 g BID)
- High Dose (Type: EXPERIMENTAL): A0001 (0.75 g BID)
- Placebo (Type: PLACEBO_COMPARATOR): Placebo

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Internet Based Cognitive Behavioral Therapy Effects on Depressive Cognitions and Brain Function

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion criteria:~* Age range between 18 and 45.~* Subjects must be right handed (as measured by Edinburgh Handedness Inventory).~* The primary language of the subjects must be English~* Must have regular access to a computer with internet connection and printer (for potential MDD or MAC participants)~* DSM-IV criteria for current Major Depressive Episode according to SCID (for enrollment into MDD or MAC groups)~* Absence of any psychotropic medications for at least 2 weeks (6 weeks for fluoxetine; 6 months for neuroleptics; 2 weeks for benzodiazepines; 2 weeks for any other antidepressants)~* PHQ-9 score below 5 (for enrollment into HC group)~Exclusion criteria:~* Any history of neurological illness or brain injury~* Current or past DSM-IV Axis I disorder (for enrollment into HC group)~* Complicating medical conditions that may influence the outcome of neuropsychological assessment or functional imaging (e.g., HIV)~* Mixed or left-handedness~* Abnormal visual acuity that is not corrected by contact lenses~* Metal within the body, claustrophobia, or other contraindications for MRI~* Less than 9th grade education~* Past or current alcohol/substance dependence, or current alcohol abuse, or current or past substance abuse (i.e. past alcohol abuse is not exclusionary)~* Use of illicit drugs within the past year~* Use of marijuana within the past month~* Current use of opioid or prescribed stimulant medications~* History of a psychotic mental illness (schizophrenia or bipolar disorder)~* Current severe symptoms of depression (total score \> 23 or responding \> 1 to Question 9 for suicidal ideation in the Patient Health Questionnaire-9 Item \[PHQ-9\] (Kroenke et al., 2001))~* A PHQ-9 score below 10 (for potential MDD or MAC participants)~* Currently participating in Cognitive Behavior Therapy~* History of ECT treatment

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 45 Years
- Healthy Volunteers: f

Study Arms:
- Internet Cognitive Behavioral Therapy (Type: EXPERIMENTAL): Participants with major depressive disorder receive an 8-week long internet-based cognitive behavioral therapy program.
- Monitored Attention Control (Type: NO_INTERVENTION): Participants with major depressive disorder receive no treatment but are monitored closely for 8 weeks. Participants in this arm are offered the treatment at the end of the study.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Continuous Femoral Nerve Block Following Total Knee Replacement

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Patients undergoing unilateral, primary total knee arthropathy (TKA)~* 18-80 years of age~* Be able to understand the possible local anesthetic-related complications, study protocol, and care of the catheter and infusion pump system and are already planning on having a perineural catheter placed for postoperative analgesia~Exclusion Criteria:~* Any contraindication to femoral block/catheter~* Any comorbidity which results in moderate or severe functional limitation (American Society of Anesthesiologists \[ASA\] physical status \>2)~* Baseline oxygen saturation \< 96% on room air~* Known hepatic or renal insufficiency (creatinine level \> 1.5 mg/dL)~* Allergy to study medications (other than nonsteroidal anti-inflammatory agents \[NSAIDs\] and acetaminophen)~* Inability to communicate with the authors~* Morbid obesity (body mass index \[BMI\]\>40 kg/m2)~* History of opioid abuse or chronic regular opioid use (use within the 2 weeks prior to surgery and duration of use \> 4 weeks)

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 80 Years
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete